Dabigatran recalled over potential carcinogen
The nationwide recall is because of the detection of the nitrosamine impurity, N-nitroso-dabigatran.
Hydroxyurea underused in youth with sickle cell anemia
An expert says providers must tell families that their children need to take it every day, no matter the severity of disease.
Surviving CLL: Higher risk of other cancer DXs
A 30-year Dutch population study highlights the medical challenges facing patients with CLL, who are now living longer.
Despite limits, COVID vaccines protect CLL patients
A small German study found that, in patients with CLL, COVID-19 shots don’t boost B cells but they do strengthen T cells.
FDA approves pirtobrutinib for r/r mantle cell lymphoma
Pirtobrutinib for relapsed or refractory mantle cell lymphoma has been approved by the Food and Drug Administration.
Adding venetoclax improves ibrutinib outcomes in CLL
A small study yields sanguine news about a combination treatment, as hematologists await phase 3 results.
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
FDA approves first gene therapy for hemophilia B
The gene therapy will cost $3.5 million, making it the most expensive treatment to date.
Leukocytoclastic Vasculitis Masquerading as Chronic ITP
Idiopathic thrombocytopenic purpura (ITP) and leukocytoclastic vasculitis (LCV) can present in a similar fashion and can be very hard to...
I am not fine: The heavy toll cancer takes
“I thought I was as exhausted, and isolated, and neglected as I could get, and then he came home.”